Teva Pharmaceutical Industries Limited(TEVA) stock price and fundamentals

Drug Manufacturers - Specialty & Generic · Tel Aviv, TA

$36.73-0.90 (-2.38%)

Delayed quote: Aug 28, 2026, 11:55 AM EDT

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Tel Aviv, TA

32,008 employees

www.tevapharm.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Richard D. Francis

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1TEVA	$42.82B	$36.77	-2.26%	+108.53%	+32.11%	-2.70%	N/A
2IQV	$43.21B	$262.51	+0.05%	+39.00%	+0.22%	+13.24%	vs TEVA
3A	$43.41B	$153.71	-2.52%	+33.93%	-1.23%	+13.67%	vs TEVA
4IDXX	$43.56B	$552.26	+1.32%	-14.95%	-3.99%	+17.34%	vs TEVA
5HUM	$47.04B	$391.78	-0.22%	+34.03%	+0.34%	+9.19%	vs TEVA
6ALC	$34.91B	$71.58	-0.90%	-10.74%	-2.16%	N/A	vs TEVA

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$0.67	$0.71	$0.74	6
Quarter ending Dec 2026	$0.70	$0.74	$0.80	6
Quarter ending Mar 2027	$0.61	$0.64	$0.66	2
Quarter ending Jun 2027	$0.70	$0.73	$0.76	2

Period	Low	Avg	High	# Analysts
FY 2026	$1.94	$2.00	$2.06	7
FY 2027	$3.03	$3.07	$3.13	7

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$4.13B	$4.23B	$4.31B	5
Quarter ending Dec 2026	$4.07B	$4.21B	$4.37B	5
Quarter ending Mar 2027	$3.95B	$4.08B	$4.20B	4
Quarter ending Jun 2027	$4.12B	$4.26B	$4.39B	4

FY 2026	$16.53B	$16.56B	$16.60B	7
FY 2027	$17.25B	$17.29B	$17.35B	8

Teva Pharmaceutical Industries Limited(TEVA) stock price and fundamentals

Valuation

Yields

TEVA Price Chart

Business at a glance

TEVA Key Metrics

Total Return CAGR

TEVA Fundamental Charts

Revenue CAGR

Net Income CAGR

EPS CAGR

Operating Cash Flow CAGR

Free Cash Flow CAGR

EBITDA CAGR

TEVA Revenue by Segment

By product / business (FY 2025)

By geography (FY 2025)

TEVA Earnings Preview

Similar-Size Sector Stocks

TEVA Competitors' Key Metrics

TEVA Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

TEVA Analyst Ratings

TEVA Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates